Clinical Trials · NCT06326190
177Lu-DOTATATE for Recurrent Meningioma
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Enrollment
- 136
- Start date
- Mar 2025
- Locations
- 19 sites, 6 countries
- Primary endpoint
- Progression Free Survival (PFS)